Stock Analysis
Etropal AD (BUL:ETR) Full Year 2024 Results
Key Financial Results
- Revenue: лв15.7m (up 41% from FY 2023).
- Net income: лв87.0k (up from лв178.0k loss in FY 2023).
- Profit margin: 0.6% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Etropal AD's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - Etropal AD has 2 warning signs (and 1 which shouldn't be ignored) we think you should know about.
Valuation is complex, but we're here to simplify it.
Discover if Etropal AD might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BUL:ETR
Etropal AD
Engages in the research, development, and manufacture of disposable medical devices for dialysis in Bulgaria.
